GlassScriptPhysician profile
Surasak Phuphanich
NPI 1457469074
$2,576.61
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $227 · 2021: $2,079.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,055.00 | 2021 | |
| Novocure INC. | $235.74 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.84 | 2020 | |
| Upsher-Smith Laboratories LLC | $26.57 | 2019 | |
| Csl Behring | $24.35 | 2020 | |
| Novartis Pharmaceuticals Corporation | $22.55 | 2019 | |
| Emd Serono, INC. | $21.56 | 2020 | |
| Arbor Pharmaceuticals, INC. | $21.51 | 2020 | |
| Lilly USA, LLC | $19.35 | 2019 | |
| Kyowa Kirin, INC. | $14.21 | 2019 | |
| Biogen, INC. | $13.93 | 2020 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surasak Phuphanich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.